PATENT CLAIM ANALYSIS

Application Number: 16197865
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.

Claim (Index 17):
The antisense oligonucleotide according to  claim 16 , wherein the antisense oligonucleotide has a length from about 8 to about 128 nucleotides.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.19355
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14342776', '15963229', '15324572', '15551026', '14546124']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8387733160495568
- 35 USC 102 Novelty (BERT): 0.6067304145689906
- Combined Prediction Score: 0.8155690259015003
- Mean Citation Score: 483.71041600000007
- Max Citation Score: 578.6174
- Similarity Product: 470.7830875088453

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test